肿瘤药学2018，Vol.8Issue(2)：211-214,4.DOI:10.3969/j.issn.2095-1264.2018.02.19
伊立替康联合铂类对广泛期小细胞肺癌患者血清水平的影响及疗效分析
Clinical Effect of Irinotecan Combined with Platinum in Treatment of Broad Stage Small Cell Lung Cancer and Its Effect on Serum Level of Patients
摘要
Abstract
Objective To investigate the clinical effect of Irinotecan combined with platinum in the first line treatment of broad stage small cell lung cancer and its effect on serum level. Methods A total of 120 cases of small cell lung cancer patients in our hospital as the research objects, were randomly divided into study group and control group. The study group was treated with irinotecan plus platinum as first-line therapy (IP), while the control group was treated with etoposide combined with platinum treatment (EP). The serum levels and treatment effects of patients were observed and compared. Results The research results showed that the survival of patients in study group was significantly longer than that of the control group. The survival rate of study group was also significantly higher than that of the control group (P<0.05). Patients of the study group had significantly better effects than those of the control group (P<0.05). In the study group, the incidence of complications was significantly lower than in the control group (P<0.05). Moreover, the serum levels of the two groups showed no significant difference before treatment (P>0.05), but after treatment it was significantly better in the study group than in the control group (P<0.05). Conclusion Irinotecan was safe and effective in combination with platinum in the first line therapy for small cell lung cancer.关键词
伊立替康联合铂类一线治疗/依托泊苷联合铂类治疗/小细胞肺癌/血清水平Key words
Irinotecan combined with Platinum first-line treatment/Treatment of carboplatin combined with platinum/Small cell lung cancer/Serum level分类
医药卫生引用本文复制引用
李琛,杨晓光,洪洋,苏菁,冯平,肖丽,温翠玲..伊立替康联合铂类对广泛期小细胞肺癌患者血清水平的影响及疗效分析[J].肿瘤药学,2018,8(2):211-214,4.基金项目
河北省医学科学研究重点课题(20150471). （20150471）
